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ABSTRACT
Objective To determine the spectrum of cancers in 
adolescents and young adults (AYAs) living with and 
without HIV in South Africa.
Design Cross- sectional study with cancer records 
provided by the National Cancer Registry (NCR) and HIV 
records from the National Health Laboratory Service 
(NHLS).
Setting and participants The NHLS is the largest 
provider of pathology services in the South African public 
sector. The NCR is a division of the NHLS. We included 
AYAs (aged 10–24 years) diagnosed with cancer by 
public health sector laboratories between 2004 and 2014 
(n=8479). HIV status was obtained through record linkages 
and text mining.
Primary and secondary outcomes We determined 
the spectrum of cancers by HIV status in AYAs. We used 
multivariable logistic regression to describe the association 
of cancer in AYAs with HIV, adjusting for age, sex, ethnicity 
and calendar period. We imputed (post hoc) the HIV status 
for AYA with unknown HIV status.
Results 8479 AYAs were diagnosed with cancer, HIV 
status was known for 45% (n=3812). Of those whose 
status was known, about half were HIV positive (n=1853). 
AYAs living with HIV were more likely to have Kaposi’s 
sarcoma (adjusted OR (aOR) 218, 95% CI 89.9 to 530), 
cervical cancer (aOR 2.18, 95% CI 1.23 to 3.89), non- 
Hodgkin’s lymphoma (aOR 2.12, 95% CI 1.69 to 2.66) and 
anogenital cancers other than cervix (aOR 2.73, 95% CI 
1.27 to 5.86) than AYAs without HIV. About 44% (n=1062) 
of AYAs with HIV- related cancers had not been tested for 
HIV.
Conclusions Targeted HIV testing for AYAs diagnosed 
with cancer, followed by immediate start of antiretroviral 
therapy, screening for cervical precancer and vaccination 
against human papilloma virus is needed to decrease 
cancer burden in AYAs living with HIV in South Africa.
INTRODUCTION
In Eastern and Southern Africa, an estimated 
1.2 million adolescents aged 10–19 years are 
living with HIV.1 Young people aged 15–25 
years represent 30% of new infections.2 Chil-
dren infected with HIV perinatally are now 
more likely to live and to become adoles-
cents and young adults (AYA) compared with 
the early days of the HIV epidemic.3 4 The 
outcomes of AYAs living with HIV (AYALHIV) 
have been poor. Challenges to retain AYAs 
in care and lack of adherence may lead to 
poor virologic suppression and low CD4 cell 
counts, which endangers their health.3 5–7 
Coinfection with other oncogenic viruses is 
also common in this age group.8 9 For people 
living with HIV, immunodeficiency and coin-
fections with other oncogenic viruses are risk 
factors for developing cancer.
Several studies have shown that the risk 
of HIV- related cancers—non- Hodgkin’s 
lymphoma (NHL), Kaposi’s sarcoma (KS) and 
cervical cancer (CC) is higher in AYALHIV 
than in HIV negative AYA.10–15 In the USA, 
the incidence of leiomyosarcoma was also 
higher in AYALHIV than in their peers from 
the general population.10 However, most of 
the existing data are from settings with a low 
HIV burden, but we still know little about 
cancer burden and risk in AYALHIV in high 
HIV burden African countries, like South 
Africa. Estimating the relationship between 
cancer and HIV is important to determine 
Strengths and limitations of this study
 ► This is the first nationwide study in South Africa to 
compare the distribution of cancers in adolescents 
and young adults (AYAs) by HIV status.
 ► The record linkage and the additional results deter-
mined from the text mining process ensured that we 
extracted the maximum available HIV results.
 ► The record linkage and the additional results deter-
mined from the text mining process ensured that we 
extracted the maximum available HIV results.
 ► We assumed a CD4 cell count test indicates being 
HIV positive but CD4 testing maybe performed for 
other reasons.
 ► Since this was a population of only AYAs diagnosed 
with cancer, the ORs could be overestimated or 
underestimated depending on the frequency of the 
cancer.
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their additional healthcare needs and to provide insights 
on potential mechanisms for prevention of cancer devel-
opment in AYALHIV.
We aimed to evaluate the spectrum and cancers asso-
ciated with HIV in AYAs at a national level. The South 
African HIV Cancer Match (SAM) study was created to 
identify the risk factors and spectrum of malignancies in 
people living with HIV based on routine reports.16 In this 
cross- sectional analysis, which is a subproject of the SAM 
study, we included all AYAs with a pathology- confirmed 
cancer diagnosis. We examined the proportion of cancer 
diagnoses with or without HIV infection and the factors 
associated with cancer in AYALHIV.
METHODS
Study design and setting
This was a cross- sectional study with cancer data provided 
by the National Cancer Registry (NCR) and HIV- related 
laboratory data from the National Health Laboratory 
Service (NHLS). The NHLS is the largest provider of 
diagnostic pathology services in the South African public 
sector (estimated coverage is over 80% of the South 
African population).17 The NHLS includes the National 
Institute of Communicable Diseases, the National Insti-
tute of Occupational Health and the pathology- based 
NCR. The Corporate Data Warehouse (CDW) is the 
centralised data centre of the NHLS where all the data on 
tests performed in its laboratories are stored.
Inclusion criteria
We included all AYAs with a primary incident cancer 
recorded from 2004 to 2014 in NCR records irrespective 
of HIV status. Adolescence was defined as 10–19 years 
and young adulthood as 20–24 years at the time of cancer 
diagnosis, based on WHO and South African Department 
of Health definitions.6 18 We excluded cancer precursors 
and only retained laboratory- confirmed cancer records 
that contained the International Classification of Disease 
in Oncology V.3 topography and morphology descrip-
tions.19 If a person had two different cancers at different 
sites, they were considered as two individual records 
(multiple primaries).
Outcome and exposure variables
The main exposure was HIV infection and the main 
outcome cancer diagnosis stratified by morphological type 
and subtype where applicable. HIV status was determined 
from HIV diagnostic tests (enzyme- linked immnunosor-
bent assay, qualitative PCR and rapid HIV tests) and HIV 
monitoring tests (CD4 cell counts and HIV RNA viral 
loads). We assumed an individual was HIV positive if any 
diagnostic test was positive or if monitoring tests (CD4 cell 
count, HIV RNA viral load) were recorded. We used text 
mining methods to extract additional HIV results from 
the clinical history section of cancer pathology reports 
as discussed in detail elsewhere.20 We assigned the HIV 
status irrespective of the cancer diagnosis date.
We used deterministic and probabilistic record linkages 
(PRL) as well as text mining to determine HIV status. 
For the deterministic record linkage, we used episode 
numbers as linkage variable. Episode number refers to 
tests that were requested for a patient at the same time 
by the health practitioner and assigned the same unique 
identifier. About 65% of the all linkages were matched 
using the episode number. Using PRL, the CDW created 
a unique patient identifier for records belonging to 
the same person. As described in detail elsewhere.20 
The CDW uses names, surnames and dates of births as 
linkage variables, which are fed into the PRL linkage algo-
rithm. First names and surnames have a weight of 40% 
each, and date of birth a weight of 20%. Records with 
a recorded national identity number are exact matches. 
To be considered a match, the cumulative score has to 
reach 90% or above. The data from the CDW have been 
evaluated for completeness and accuracy and validated 
as a good source of data for research on HIV in South 
Africa.21 After this, we then added the text mining data. 
We used NCR records to determine demographic char-
acteristics. Where missing, the NCR imputes ethnicity 
based on surnames using known surname- ethnicity pair-
ings.22 Ethnicity was grouped into Black and Other for 
comparison purposes because few subjects belonged to 
other population subgroups. We divided calendar years 
into three periods: the early years of combination antiret-
roviral therapy (ART) (2004–2008); later years (2009–
2011); and, the most recent period (2012–2014). We 
selected cut- offs for the calendar periods to correspond 
with changes in ART guidelines in South Africa during the 
study period.23 We grouped cancers of vulva, penis, vagina 
and anus as anogenital cancers other than CC. We evalu-
ated NHL as a group, and at each of its subtypes: Burkitt 
lymphoma; diffuse large B cell lymphoma (DLBCL); 
diffuse immunoblastic large B cell lymphoma (DILBCL); 
follicular NHL and mature T cell NHL.
Data analysis
For descriptive purposes, we presented sex, ethnicity 
(Asian, black, coloured (mixed race) and white) and age 
stratified by HIV status (positive/negative/unknown). We 
then showed the frequency and spectrum of the top 20 
cancers in AYAs stratified by HIV status (positive/nega-
tive/unknown) and by sex. We used a logistic regres-
sion model to determine the association between HIV 
and cancer in AYAs. For each cancer, we used records 
without the cancer under study as the comparison group, 
including cancers with an infectious aetiology. We adjusted 
the models using age (adolescence vs young adults), 
sex (male vs female, except for sex- specific cancers), 
ethnicity (black vs other) and ART era. We restricted our 
main analyses to cancers in AYAs with known HIV status, 
so all AYA were either HIV positive or HIV negative. We 
assessed interactions between HIV and other factors of 
interest (age, sex, ethnicity and calendar period) and 
adjusted models for interaction analysis for age, sex, 
ethnicity and calendar period. To test for significance of 
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the interaction, we used likelihood ratio tests to compare 
logistic regression models with and without the interac-
tion terms at 5% significance level. Stata V.15.1 was used 
for all analyses (StataCorp).
Sensitivity analysis
As a sensitivity analysis, we used multiple imputation 
methods to impute missing HIV results for 4431 patients 
with cancer with unknown HIV status. We included HIV 
status (the primary exposure), cancer diagnosis period, 
sex, age and ethnicity in our imputation model. Since 
ethnicity was already imputed by the NCR using surname- 
ethnicity pairings, we excluded records that still had 
missing ethnicity data (4%; n=368). We also excluded 
records with missing sex as they were few (0.09%; n=8). 
We used multivariable imputation with chained equations 
to generate 15 imputed datasets that we combined to give 
a pooled estimate (OR). For each cancer, we fitted multi-
variable logistic regression models adjusting for age, sex, 
ethnicity and calendar period. We compared the results 
from the imputed dataset with the main complete case 
analysis. Online supplemental table S1 compares the 
proportional distribution of known and unknown HIV 
status by the variables in the imputation model.
Patient and public involvement
The study is based on routinely collected laboratory data 
therefore no patients were involved in the design, conduct, 
reporting, or dissemination plans of our research. Due 
to the anonymous nature of the data, we cannot dissem-
inate the results of analyses of the data directly to study 
participants.
RESULTS
Over the 11 years of study period, 8479 AYAs were diag-
nosed with cancer. The median age was 20 years (IQR: 
15–23) and over half (n=4466) of all recorded cancer 
cases were diagnosed in young adults (20–24 years). Girls 
and women were 54% (n=4 605) of the AYA population; 
most AYAs with cancer were black 75% (n=6376). About 
45% (n=3819) of AYAs with cancer were assigned an HIV 
status; half of those with known status were HIV positive 
(n=1855). When we compared AYA patients with cancer 
with and without HIV, the median age of AYA patients 
with cancer with HIV was 22 years (IQR: 19–23) while it 
was 18 years in those without HIV (IQR: 13–21). In our 
analysis, AYAs with HIV were more often female (67% vs 
45%; p<0.001) and more often black population (86% vs 
64%) (table 1) as compared with AYA without HIV. The 
proportion of AYA with unknown HIV status declined 
across the calendar periods (figure 1).
The most frequently diagnosed cancer was KS, 
followed by leukaemia and bone cancer (figure 2, abso-
lute numbers in online supplemental table S2). Non- 
AIDS defining cancers (NADCs) made up 68% (n=5803) 
of histologically diagnosed cancers. In AYA with AIDS 
defining cancers (ADCs, 44% (n=1062) of patients had 
unknown HIV status vs 59% (n=3411) of AYA with NADC. 
The HIV status of 44% (n=617) of AYA diagnosed with 
KS was unknown, and the HIV status of 43% (n=269) 
of AYA diagnosed with NHL was unknown (figure 1). 
Haematological cancers were the most common cancers 
in AYAs without HIV: leukaemia was the most frequent 
diagnosis (n=449), followed by Hodgkin’s lymphoma 
(n=246). Bone cancers were also more common in AYAs 
without HIV (n=197). In HIV negative AYAs, the top 
five cancers were similar for male and female patients 
but HIV negative male AYAs had a higher proportion of 
Hodgkin’s lymphoma and bone cancers compared with 
female AYAs.
Among those with recorded HIV status, KS, NHL and 
Hodgkin’s lymphoma, leukaemia and CC were the most 
frequent cancers in AYALHIV (figure 1). The top five 
most frequent cancers among female AYAs with HIV 
were KS, NHL, CC, Hodgkin’s lymphoma and leukaemia 
(online supplemental figure S1). For male AYAs with HIV, 
the most frequently diagnosed cancers were KS, NHL, 
leukaemia, Hodgkin’s lymphoma and connective tissue 
cancers. The proportion of KS cases was higher in female 
AYAs with HIV (71%, n=998) than in male AYAs with HIV 
(29%, n=409).
The logistic regression analysis revealed higher odds of 
ADCs than to NADCs in AYAs with HIV (table 2). When 
we compared HIV positive AYAs to HIV negative AYAs, the 
adjusted OR for AYAs with HIV was 218 (95% CI 89.9 to 
530) for KS, 2.18 (95% CI 1.23 to 3.89) for CC, and 2.12 
(95% CI 1.69 to 2.66) for NHL. The odds of specific NHL 
subtypes like Burkitt lymphoma, DLBCL and DILBCL 
were higher in AYALHIV than in AYAs without HIV 
(table 2). Anogenital cancers other than CC were also 
strongly associated with HIV; adjusted OR was 2.73 (95% 
CI 1.27 to 5.86). We did not observe significant odds of 
leiomyosarcoma in AYALHIV but, of the eight recorded 
leiomyosarcoma cases with a known HIV result, six were 
HIV positive and five were female. Odds were not high for 
HIV and Hodgkin’s lymphoma or HIV and liver cancer.
Interaction tests determined that age modified the 
odds of NHL in AYALHIV; adolescents with HIV had 
higher odds of NHL (adjusted OR 3.17; 95% CI 2.35 to 
4.28) than young adults with HIV (adjusted OR 1.29; 
95% CI 0.93 to 1.79; p value for interaction <0.0001). 
Ethnicity also modified the odds of Burkitt lymphoma in 
HIV positive AYAs; black AYAs with HIV had higher odds 
of Burkitt lymphoma (adjusted OR 3.84; 95% CI 2.10 to 
7.04) than non- black AYAs with HIV (adjusted OR 1.35; 
95% CI 0.43 to 4.28, p value for interaction=0.0199). 
In the sensitivity analysis that used the imputed dataset 
multivariable analysis results were similar to the main 
analysis of subjects with a known HIV status (table 2). 
Specifically the odds of KS (adjusted OR 208; 95% CI 
83.9 to 519, CC (adjusted OR 2.70; 95% CI 1.31 to 2.17) 
and anogenital cancers other than cervix (adjusted OR 
2.61; 95% CI 1.11 to 6.11) were higher in AYALHIV 
compare to HIV negative AYAs.
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DISCUSSION
We observed an association among AYAs between HIV 
and ADCs and anogenital cancers other than CC, 
including penile, anal, vulvar and vaginal cancers. Among 
those living with HIV, the proportion of KS was higher in 
girls and young women than in boys and young men. The 
combined odds of cancers not associated with HIV were 
higher in AYALHIV than in those without HIV. We could 
not ascertain the HIV status of many AYAs diagnosed 
with HIV- related cancers, however, a sensitivity analyses 
using imputed data yielded qualitatively similar results. 
We observed higher odds of Burkitt lymphoma black 
AYALHIV compared with those without HIV and higher 
odds of NHL in adolescents living with HIV compared 
with young adults living with HIV.
It is known that the risk of ADCs is higher in 
AYALHIV.10–12 14 24 25 In our study, KS was the cancer most 
strongly associated with HIV. HIV cohort studies have 
reported increased KS incidence among children and 
adolescents under 16.10 12 A multicohort study found 
KS risk was higher in HIV positive adolescents and chil-
dren from Southern Africa than in the same age group 
in other regions of the world.26 In South Africa, where 
treatment and retention in care rates for AYAs with HIV 
are low,3 poorly controlled HIV infection among AYAs 
may increase the odds of KS. The South African National 
HIV Prevalence Survey of 2017 revealed that about 60% 
of young adults (ages 15–24) living with HIV were not on 
ART.27 Untreated AYALHIV are likely to develop immu-
nodeficiency which increases their risk of developing 
Table 1 Demographic characteristics of adolescents and young adults with a cancer diagnosis stratified by HIV status in the 
South African public health sector, 2004–2014
HIV negative HIV positive HIV unknown
n (%) n (%) n (%)
Age
Median age (IQR) (years) 18 (13–21) 22 (19–23) 20 (16–22)
  10–14 635 (32.3%) 200 (10.8%) 922 (19.8%)
  15–19 585 (29.8%) 338 (18.2%) 1331 (28.6%)
  20–24 744 (37.9%) 1317 (71.0%) 2407 (51.7%)
Sex
  Female 877 (44.7%) 1247 (67.2%) 2484 (53.3%)
  Male 1087 (55.3%) 607 (32.7%) 2169 (46.5%)
  Missing 0 (0%) 1 (0.1%) 7 (0.2%)
Ethnicity
  Asian 34 (1.7%) 14 (0.8%) 106 (2.3%)
  Black 1258 (64.1%) 1593 (85.9%) 3525 (75.6%)
  Coloured (mixed race) 323 (16.4%) 103 (5.6%) 317 (6.8%)
  White 274 (14.0%) 74 (4.0%) 487 (10.5%)
  Missing 75 (3.8%) 71 (3.8%) 225 (4.8%)
Type of cancer
  Non- AIDS defining cancer 1699 (86.5%) 697 (37.6%) 3411 (73.2%)
  AIDS defining cancer 206 (10.5%) 1129 (60.9%) 1062 (22.8%)
  Primary site unknown 59 (3.0%) 29 (1.6%) 187 (4.0%)
ART calendar period
  2004–2007 594 (30.2%) 500 (27.0%) 2062 (44.2%)
  2008–2011 822 (41.9%) 784 (42.3%) 1647 (35.3%)
  2012–2014 548 (27.9%) 571 (30.8%) 951 (20.4%)
Multiple primary cancer
  Yes 10 (0.50%) 13 (0.70%) 31 (0.67%)
  No 1954 (99.5%) 1842 (99.3%) 4629 (99.3%)
Total 1964 (100%) 1855 (100%) 4660 (100%)
Multiple primary cancer refers to an individual with more than one cancer at different primary sites.
ART, antiretroviral therapy; IQR, interquartile range 
.
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KS.26 The higher proportion of KS in females in our study 
might also be a reflection of the high proportion of HIV 
observed in female AYAs in our study.
The odds of CC and human papilloma virus (HPV) 
related cancers such as anogenital cancers in this young 
adult population may be increased for several reasons. In 
South Africa in 2017, girls and young women were much 
more likely to be HIV positive (10.9% prevalence) than 
boys and young men (4.8%).27 Biological factors may 
account for higher HIV prevalence in girls and young 
women, along with socioeconomic factors that encourage 
risky sexual behaviour including transactional and inter-
generational sexual relationships.27 High prevalence 
and poorly controlled HIV can increase the risk of HPV 
coinfection in an age group less likely to be screened for 
precancerous cervical lesions, which in turn increases CC 
risk and risk of other anogenital cancers among AYAs. A 
study in the Western Cape province of South Africa found 
AYALHIV had higher HPV prevalence and more high- 
risk HPV subtypes than AYAs without HIV.8 In contrast 
to other studies on cancer in AYALHIV, we observed 
three CC cases in AYAs aged between 14 and 16 years; two 
of these young women were HIV positive. HIV cohorts 
in South Africa and the USA have not identified CC in 
children and adolescents under 16 years old,10 14 but CC 
risk and incidence has been on the increase in the ART 
era for those between 18 and 24 years old.28 Early sexual 
debut, and subsequent early exposure to causative agents 
like HPV may explain this early presentation with CC in 
South Africa.8 29 30
Lymphomas are often misdiagnosed as tuberculosis in 
people living with HIV in our setting, slowing lymphoma 
diagnosis and worsening patients’ prognosis.31 This 
might explain the significantly lower odds of Hodgkin 
lymphoma, a cancer associated with HIV in our study 
population. Like other studies, we found NHL was asso-
ciated with HIV.10 14 NHL is associated with poor adher-
ence to ART and low rates of viral suppression, and NHL 
risk is high in HIV positive individuals on ART even when 
their disease is controlled.14 32 33 This may be because HIV 
activates the CD40 receptors on B- cells like Epstein- Barr 
virus (EBV) would in EBV- related cancers such as Burkitt 
lymphoma.32 From a national cohort study in South 
Africa, among AYAs, the incidence of NHL decreased with 
increasing CD4 cell counts. We expect poor ART coverage 
and retention in care among AYAs with HIV increases 
this risk, but researchers still need to determine NHL 
risk in virally suppressed and non- suppressed patients 
in our setting. From our interaction analysis, the odds 
of NHL were higher in adolescents with HIV compared 
with young adults with HIV. This observation could be 
as a result of the predominance of lymphoblastic and 
Burkitt lymphoma, which are more common in younger 
ages.34 We also found that the odds of Burkitt lymphoma 
were higher in HIV positive black AYAs compared with 
the other ethnicities. Burkitt lymphoma in South Africa is 
more likely to be found in white children aged 0–14 years 
than in black children,22 but this is a different age group 
to that in our study.
Other studies identified an association between leio-
myosarcoma and HIVs.13 Although not statistically signifi-
cant, the odds of leiomysorcoma were higher in AYALHIV 
than in AYAs without HIV. Since leiomyosarcoma is rare, 
the association between leiomyosarcoma and HIV needs 
further study. Likewise, after we adjusted for the inter-
action of HIV with age and calendar period, AYALHIV 
had an increased risk of connective tissue cancer, but this 
finding did not reach statistical significance.
We also evaluated HIV unknowns. In South Africa, 
HIV testing uptake is lower in AYAs than in adults27 
and is mostly opportunistic.35 Therefore, including this 
would again stress the importance of patients with cancer 
and AYAs as a whole to be tested for HIV. Although the 
percentage of subjects with unknown HIV status decreased 
over calendar periods, HIV testing for AYA diagnosed 
Figure 1 Distribution of HIV unknowns across the study 
period among AYAs with cancer. The trend analysis for 
proportions was statistically significant across all strata of 
HIV status (p<0.001) for all HIV status stratified by year of 
cancer diagnosis. AYAs, adolescents and young adults.
Figure 2 Top 21 cancer in adolescents and young adults in 
the South African public health sector stratified by HIV status. 
Brain, CNS, brain central nervous system; SCC of skin, 
squamous cell carcinoma of skin.
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with HIV- related cancers remained low. The HIV status of 
many AYAs with KS, CC and NHL was unknown. An AYA 
is most likely to be tested if they present to a healthcare 
facility with symptoms linked to a sexually transmitted 
infection or if a female AYA visits a reproductive health 
clinic.36
Because AYALHIV are at higher risk of ADCs and 
anogenital cancers and many AYAs with HIV- related 
cancers are not tested for HIV, HIV programmes for AYAs 
should extend HIV testing coverage, link AYAs to care 
and make sure to retain them. AYALHIV have a higher 
risk of cervical and other anogenital cancers because of 
the high frequency of HPV coinfection, exacerbated by 
sexual debut and young age. In addition, we also recom-
mend that physicians maintain a high suspicion index 
for lymphomas and take care no to misdiagnose them as 
tuberculosis, thereby delaying care.
Our study is the first nationwide study to compare the 
distribution of cancers in AYAs by HIV status in South 
Africa. The record linkage and the additional results 








OR (95% CI) OR (95% CI) OR (95% CI)
AIDS defining cancers 13.3 (11.2 to 15.8) 12.0 (9.92 to 14.5) 11.8 (9.75 to 14.3)
  Kaposi’s sarcoma 288 (119 to 696) 218 (89.9 to 530) 208 (83.9 to 519)
  NHL 1.64 (1.34 to 2.00) 2.12 (1.69 to 2.66) 2.12 (1.64 to 2.74)
   Burkitt lymphoma 1.99 (1.30 to 3.05) 2.65 (1.64 to 4.28) 2.78 (1.75 to 4.37)
   NHL- NOS 3.31 (1.72 to 6.37) 4.28 (2.06 to 8.92) 4.00 (1.78 to 8.99)
   DLBCL- NOS 1.52 (1.11 to 2.09) 2.03 (1.42 to 2.90) 1.97 (1.34 to 2.91)
   DILBCL- NOS 3.61 (1.64 to 7.97) 4.75 (2.01 to 11.3) 4.80 (2.04 to 11.3)
   Mature T- cell- NHL 0.94 (0.36 to 2.44) 1.11 (0.38 to 3.23) 1.05 (0.37 to 2.97)
   Follicular NHL 0.79 (0.18 to 3.55) 0.93 (0.12 to 6.89) 0.96 (0.09 to 9.80)
  Cervical cancer 4.62 (2.75 to 7.75) 2.18 (1.23 to 3.89) 2.70 (1.31 to 5.53)
Non- AIDS defining cancer 0.09 (0.08 to 0.11) 0.11 (0.09 to 0.13) 0.11 (0.09 to 0.12)
  Virus- related cancers 0.56 (0.46 to 0.68) 0.64 (0.52 to 0.80) 0.61 (0.48 to 0.79)
   Anogenital cancers other than cervix 3.91 (2.00 to 7.65) 2.73 (1.27 to 5.86) 2.61 (1.11 to 6.11)
   Hodgkin’s lymphoma 0.48 (0.38 to 0.60) 0.60 (0.47 to 0.78) 0.58 (0.44 to 0.78)
   Liver and bile duct 0.27 (0.14 to 0.55) 0.28 (0.13 to 0.61) 0.26 (0.11 to 0.64)
  Virus- unrelated non- AIDS defining cancers 1.88 (1.57 to 2.25) 1.69 (1.38 to 2.07) 1.70 (1.33 to 2.17)
   Bone 0.23 (0.16 to 0.32) 0.29 (0.21 to 0.42) 0.29 (0.20 to 0.41)
   Brain- CNS 0.33 (0.21 to 0.53) 0.35 (0.20 to 0.60) 0.37 (0.17 to 0.80)
   Colorectal 0.25 (0.14 to 0.44) 0.15 (0.08 to 0.28) 0.15 (0.07 to 0.29)
   Connective tissue 0.41 (0.30 to 0.57) 0.44 (0.31 to 0.64) 0.46 (0.31 to 0.69)
   Eye 1.85 (1.05 to 3.27) 1.11 (0.58 to 2.13) 1.03 (0.45 to 2.32)
   Haematology 0.33 (0.18 to 0.58) 0.63 (0.34 to 1.18) 0.67 (0.33 to 1.36)
   Leukaemia 0.22 (0.18 to 0.27) 0.29 (0.23 to 0.37) 0.30 (0.23 to 0.39)
   Leiomyosarcoma 3.18 (0.64 to 15.8) 2.13 (0.38 to 11.9) 2.01 (0.31 to 12.9)
   Myeloma 0.79 (0.18 to 3.55) 0.62 (0.09 to 4.03) 0.63 (0.07 to 5.57)
   Ovary 0.51 (0.30 to 0.87) 0.48 (0.26 to 0.87) 0.58 (0.31 to 1.08)
   SCC skin 1.99 (1.06 to 3.74) 1.21 (0.60 to 2.44) 1.07 (0.50 to 2.27)
   Skin 0.61 (0.29 to 1.29) 0.44 (0.19 to 1.02) 0.37 (0.15 to 0.87)
   Thyroid 0.46 (0.19 to 1.12) 0.29 (0.11 to 0.77) 0.31 (0.09 to 1.05)
   Testis 0.19 (0.08 to 0.42) 0.28 (0.11 to 0.68) 0.21 (0.07 to 0.57)
The multivariable analyses adjusted for age, sex (where applicable), ethnicity and calendar period. Imputation was done under the missing at 
random assumption for each cancer type. The variables used to impute for missing HIV status were ethnicity, sex and cancer diagnosis year. 
The imputed analyses are multivariable analysis adjusting for age, sex (where applicable), ethnicity and calendar period.
AYAs, adolescents and young adults; CNS, central nervous system; DILBCL, diffuse immunoblastic large B- cell lymphoma; DLBCL, diffuse 
large B- cell lymphoma; NHL, non- Hodgkin’s lymphoma; NOS, not otherwise specified; SCC, squamous cell carcinoma.
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determined from the text mining process ensured that we 
extracted the maximum available HIV results. Our study 
has several limitations. As in other HIV cohort studies37 38 
that have used CD4 cell counts to create HIV cohorts, 
we assumed that anyone who had a CD4 cell count test 
was HIV positive. It is possible, that CD4 cell count tests 
might be performed for other reasons. We think that this 
possibility is low in our study setting, because according to 
South African management guidelines,39 since CD4 tests 
are usually administered after a positive HIV test. The 
proportion of patients whose HIV status was unknown 
might not be representative of the entire HIV population 
in South Africa, because our study included only those 
who had laboratory HIV tests. Rapid test results are less 
likely to appear in the NHLS database in the later years 
compared with the beginning of our study period (only 
10% of cancers had a rapid test result). Our study shares 
the same limitations as the proportionate incidence anal-
ysis. Since out study population included only AYAs with 
cancer just like in proportionate incidence analysis, the 
ORs may have been overestimated. For the most common 
cancers, the OR might reflect how frequently a cancer 
is observed and not the actual strength of association 
between HIV and the cancer. There is also a potential of a 
type one error as a result of multiple hypothesis testing on 
the same data set for the different cancers. However, our 
results are generally in line with what has been observed 
in adults in South and AYAs in other settings. Using all 
other cancers as a comparison group may have also led to 
underestimating the strength of the association, especially 
for cancers with overlapping risk factors. In addition, this 
limits generalisability of our findings to the South African 
population. However, this does not necessarily mean that 
the effects of the last two limitations cancel out. Our study 
was not designed to assess associations between markers 
of immunosuppression and cancer risk. In our study, HIV 
negative individuals do not have CD4 cell count measure-
ments and could, therefore, not be in included for such 
comparisons. Each patient with cancer was assigned only 
one HIV- related test. Therefore, although we used CD4 
cell counts to assign HIV status, we did not assess the 
sequence of CD4 cell counts and hence cannot establish 
whether the values were the baseline CD4 cell measure-
ments or the most recent CD4 cell measurements. Lastly, 
those assigned HIV status using other tests would not 
have a CD4 cell count, which, would then result in a selec-
tion bias. Because of these reasons we did not adjust for 
markers of immunosuppression such as HIV RNA viral 
loads and CD4 cell counts in our analyses. We were also 
unable to assess the odds of cancer by HIV transmission 
route, for example, vertical transmission against other 
transmission routes. Finally, the HPV vaccine has been 
rolled out in 2014 to girls between the ages of 9 and 13 
years, therefore, we are not able to evaluate the impact of 
HPV vaccination on cancer risk with our data that cover 
the time period 2011–2014.
CONCLUSION
This is the first nationwide study in South Africa to 
compare the distribution of cancers in AYAs by HIV status. 
ADCs and anogenital cancers other than cervix cancer 
were more common in HIV positive than in HIV nega-
tive AYAs. AYAs with cancer are a key population for HIV 
testing, however, this study suggests that many AYAs with 
ADCs are not tested for HIV. Targeted HIV testing for 
AYAs should be followed by the immediate start of ART 
after a positive HIV diagnosis, accompanied by screening 
for cervical pre- cancer and vaccination against HPV to 
decrease cancer burden in AYALHIV in South Africa.
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Online Supplement Table S1: Distribution of AYAs with known and unknown HIV status by 
characteristics used in the imputation model 
Characteristics 
Unknown HIV 
status n (%) 
Known HIV status 
n (%) 
Age [years]   
10 162 (47.1%) 182 (52.9%) 
11 152 (46.8%) 173 (53.2%) 
12 160 (48.8%) 168 (51.2%) 
13 190 (52.9%) 169 (47.1%) 
14 210 (65%) 113 (35%) 
15 210 (56.3%) 163 (43.7%) 
16 233 (61.5%) 146 (38.5%) 
17 259 (61.4%) 163 (38.6%) 
18 276 (57.4%) 205 (42.6%) 
19 284 (57.3%) 212 (42.7%) 
20 337 (56.5%) 259 (43.5%) 
21 401 (57.9%) 291 (42.1%) 
22 451 (53.6%) 391 (46.4%) 
23 530 (53.2%) 467 (46.8%) 
24 576 (50.3%) 570 (49.7%) 
Sex   
Female 2374 (53.6%) 2051 (46.4%) 
Male 2057 (55.9%) 1621 (44.1%) 
Ethnicity   
Asian 106 (68.8%) 48 (31.2%) 
Black 3521 (55.3%) 2850 (44.7%) 
Coloured 317 (42.7%) 426 (57.3%) 
White 487 (58.3%) 348 (41.7%) 
Cancer diagnosis date   
2004 575 (81%) 135 (19%) 
2005 415 (61.8%) 257 (38.2%) 
2006 492 (62.8%) 292 (37.2%) 
2007 458 (57.1%) 344 (42.9%) 
2008 443 (54.2%) 375 (45.8%) 
2009 438 (53.3%) 383 (46.7%) 
2010 369 (50%) 369 (50%) 
2011 327 (43.6%) 423 (56.4%) 
2012 348 (42.9%) 463 (57.1%) 
2013 283 (46.2%) 329 (53.8%) 
2014 283 (48.4%) 302 (51.6%) 
Cancer site   
Anus 13 (56.5%) 10 (43.5%) 
BCC 60 (85.7%) 10 (14.3%) 
Bladder 18 (85.7%) 3 (14.3%) 
Bone 467 (66.3%) 237 (33.7%) 
Brain, CNS 192 (67.8%) 91 (32.2%) 
Breast 137 (71%) 56 (29%) 
Burkitt lymphoma 40 (30.5%) 91 (69.5%) 
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Cervix 128 (57.9%) 93 (42.1%) 
Colorectal 108 (59.7%) 73 (40.3%) 
Connective tissue 334 (65.1%) 179 (34.9%) 
Endocrine 22 (42.3%) 30 (57.7%) 
Eye 109 (69.4%) 48 (30.6%) 
Gum 1 (100%) 0 (0%) 
Haematology other 68 (52.7%) 61 (47.3%) 
Hodgkin lymphoma 228 (39.8%) 345 (60.2%) 
Ill defined 7 (100%) 0 (0%) 
Kaposi Sarcoma 597 (43.9%) 764 (56.1%) 
Kidney 63 (61.2%) 40 (38.8%) 
Larynx 1 (25%) 3 (75%) 
Leukaemia 321 (37.3%) 539 (62.7%) 
Lip 8 (61.5%) 5 (38.5%) 
Liver & Bile duct 70 (61.4%) 44 (38.6%) 
Lung 23 (76.7%) 7 (23.3%) 
Melanoma 76 (81.7%) 17 (18.3%) 
Mesothelioma 3 (100%) 0 (0%) 
Mouth 32 (60.4%) 21 (39.6%) 
Myeloma 5 (45.5%) 6 (54.5%) 
Naso-Oropharynx 95 (51.1%) 91 (48.9%) 
Non Hodgkin lymphoma 253 (42.2%) 347 (57.8%) 
Oesophagus 14 (66.7%) 7 (33.3%) 
Other specified 42 (57.5%) 31 (42.5%) 
Ovary 90 (59.6%) 61 (40.4%) 
Pancreas 4 (57.1%) 3 (42.9%) 
Penis 3 (50%) 3 (50%) 
Placenta 53 (65.4%) 28 (34.6%) 
Primary site unknown 172 (66.9%) 85 (33.1%) 
Prostate 15 (83.3%) 3 (16.7%) 
SCC of skin 120 (74.1%) 42 (25.9%) 
Salivary gland 51 (68%) 24 (32%) 
Skin other 108 (78.8%) 29 (21.2%) 
Small intestine 7 (77.8%) 2 (22.2%) 
Stomach 24 (58.5%) 17 (41.5%) 
Testis 98 (69%) 44 (31%) 
Thyroid 89 (80.2%) 22 (19.8%) 
Tongue 7 (77.8%) 2 (22.2%) 
Uterus 28 (57.1%) 21 (42.9%) 
Vagina 10 (50%) 10 (50%) 





BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-043941:e043941. 11 2021;BMJ Open, et al. Dhokotera T
Online Supplement Table S2: Top 20 cancer in AYAs in the South African public health sector stratified 
by HIV status 
Cancer Site HIV positive HIV negative HIV unknown 
NADC   697 1699 3411 
ADC 1129 206 1062 
Kaposi Sarcoma 786 5 617 
Leukaemia 113 449 338 
Bone 46 197 496 
NHL 206 150 269 
Hodgkin lymphoma 119 246 235 
Connective tissue 54 134 348 
Brain, CNS 24 75 208 
Cervix 76 18 132 
Breast 27 30 140 
Naso-oropharynx 30 65 102 
Colorectal 15 62 114 
SCC of Skin 28 15 128 
Eye 33 19 114 
Ovary 21 43 94 
Testis 7 39 102 
Skin Other 11 19 114 
Haematology other 15 48 73 
Liver and Bile duct 10 38 76 
Thyroid 7 16 96 
Kidney 7 34 65 
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Figure S1: Top five cancers in AYAs stratified by sex and HIV status 
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